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The cfr (chloramphenicol-florfenicol resistance) gene encodes a 23S rRNA methyltransferase that confers
resistance to linezolid. Detection of linezolid resistance was evaluated in the first cfr-carrying human hospital
isolate of linezolid and methicillin-resistant Staphylococcus aureus (designated MRSA CM-05) by dilution and
diffusion methods (including Etest). The presence of cfr was investigated in isolates of staphylococci colonizing
the patient’s household contacts and clinical isolates recovered from patients in the same unit where MRSA
CM-05 was isolated. Additionally, 68 chloramphenicol-resistant Colombian MRSA isolates recovered from
hospitals between 2001 and 2004 were screened for the presence of the cfr gene. In addition to erm(B), the
erm(A) gene was also detected in CM-05. The isolate belonged to sequence type 5 and carried staphylococcal
chromosomal cassette mec type I. We were unable to detect the cfr gene in any of the human staphylococci
screened (either clinical or colonizing isolates). Agar and broth dilution methods detected linezolid resistance
in CM-05. However, the Etest and disk diffusion methods failed to detect resistance after 24 h of incubation.
Oxazolidinone resistance mediated by the cfr gene is rare, and acquisition by a human isolate appears to be
a recent event in Colombia. The detection of cfr-mediated linezolid resistance might be compromised by the use
of the disk diffusion or Etest method.
Linezolid is an oxazolidinone antibiotic that binds to the 50S
subunit of bacterial ribosomes and inhibits protein synthesis
(25). Linezolid is currently approved for the treatment of in-
fections caused by methicillin-susceptible and methicillin-resis-
tant Staphylococcus aureus (MSSA and MRSA, respectively)
strains and vancomycin-resistant enterococci. Resistance has
developed sporadically during therapy in both enterococci (8)
and S. aureus (29). The most common mechanism of linezolid
resistance involves mutations in the central loop of domain V
of the 23S rRNA. The most frequent mutation associated with
linezolid resistance in both staphylococci and enterococcal
clinical strains is G2576T (Escherichia coli 23S rRNA gene
numbering) (8, 25, 29). Another mutation (T2500A) was char-
acterized in a single patient bloodstream isolate of MRSA
(17). Some additional mutations that have been found solely in
vitro include the following: G2447T in S. aureus and G2505A,
G2512T, G2513T, and C2610G in enterococci (20, 31). Most
bacteria possess multiple copies of the 23S rRNA gene, with
strains of S. aureus having five or six rRNA operons. The
number of rRNA genes mutated depends on the dose and
duration of linezolid exposure and has been shown to influence
the level of linezolid resistance (3, 15). Also, a linezolid-resis-
tant isolate of S. pneumoniae was found to contain a 6-bp
deletion in the gene encoding riboprotein L4 (30).
Nonmutational resistance to oxazolidinones has recently
been reported in veterinary isolates of staphylococci. In these
isolates, a gene encoding an rRNA methyltransferase (desig-
nated cfr, for chloramphenicol-florfenicol resistance) has pri-
marily been found on plasmids and appears to be capable of
horizontal transfer between staphylococci (11). The mecha-
nism of cfr-mediated resistance to linezolid and chloramphen-
icol involves the methylation of A2503 in the 23S rRNA of the
large ribosomal subunit (13).
Recently, we reported that linezolid resistance in a clinical
human MRSA isolate (designated CM-05) from Colombia was
mediated by the presence of the same cfr gene (28). The
MRSA CM-05 isolate was characterized, and it was found that,
unlike the animal isolates, the gene was located in the chro-
mosome but likely was a part of an integrated plasmid possibly
capable of excision and mobilization (28). Also, in MRSA
CM-05, the cfr gene was clustered in the chromosome with the
erm(B) gene (which encodes another rRNA methylase and
which confers resistance to macrolide, lincosamide, and strep-
togramin B antibiotics), forming a transcriptional unit desig-
nated the mlr (for modification of the large ribosomal unit)
operon (28). The presence of the mlr operon rendered the
MRSA isolate resistant to all antibiotics whose target is the
large ribosomal subunit (28).
In this work, we describe the clinical and microbiological
characteristics of cfr-mediated linezolid resistance in the
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MRSA CM-05 isolate from Colombia, including an epidemi-
ological investigation performed to track a possible source of
the organism.
CASE REPORT
A 52 year-old female with a medical history of chronic renal
failure presented to a hospital in Medellı´n, Colombia, in May
2005 with a right transtrochanteric hip fracture and, 2 days
after admission, underwent internal fixation of the right hip.
The postoperative course was complicated by severe gastroin-
testinal hemorrhage requiring laparotomy with the finding of
an actively bleeding ulcer at the ileocecal valve. Resection of
the bleeding portions and enteral anastomoses were carried
out at surgery, and wound closure was delayed. She was trans-
ferred to the intensive care unit, and ciprofloxacin (500 mg
intravenously [i.v.] every 12 h) and metronidazole (500 mg i.v.
every 8 h) were started empirically. After 3 days in the inten-
sive care unit, the patient developed nosocomial pneumonia.
Linezolid was prescribed, and two doses of 600 mg were given
i.v. One day later, cultures of a tracheal aspirate revealed an
MRSA isolate that was resistant to linezolid. Blood and urine
cultures remained negative. Antibiotics were switched to van-
comycin (1 g i.v. every 12 h) and meropenem (1 g i.v. every 8 h).
The patient’s condition continued to deteriorate, and i.v. tri-
methoprim-sulfamethoxazole was added to the regimen (15
mg/kg of body weight of the trimethoprim component divided
every 8 h). However, she died on hospital day 27 with multi-
organ failure.
MATERIALS AND METHODS
Surveillance for colonization of household contacts by linezolid-resistant
Staphylococcus aureus. Nasal and inguinal swab specimens for surveillance cul-
tures were obtained from members of the household (three individuals). Con-
tacts with animals by the patient and household members were investigated by
direct questioning. Nasal swabs were obtained from both anterior nares and
inguinal areas by using a sterile swab (Amies; Becton Dickinson, Franklin Lakes,
NJ) and transported to the laboratory, where the samples were placed into
Trypticase soy broth (Biomedics, SL, Madrid, Spain) containing 2% NaCl and
finally inoculated onto salt mannitol agar (Biomedics, SL). Single colonies were
isolated, Gram stained, and tested for the presence of coagulase. Final identifi-
cation to the species level was performed by a multiplex PCR assay, as described
before (16). Phenotypic resistance to methicillin was evaluated in Mueller-Hin-
ton agar (Biomedics, SL) supplemented with 4% NaCl and oxacillin (6 g/ml),
as recommended by the Clinical and Laboratory Standards Institute (CLSI) (5).
All individuals were asked to sign an informed consent, and the surveillance
protocol was approved by the ethics committees of local institutions.
Susceptibility testing. The MICs of linezolid, vancomycin, teicoplanin, tri-
methoprim-sulfamethoxazole, tetracycline, erythromycin, clindamycin, chloram-
phenicol, and ciprofloxacin were determined for the clinical isolates by an agar
dilution method following the recommendations of the CLSI (5). The clinical S.
aureus isolates included the 1 from the index case and 16 other isolates recovered
from the same hospital during the following 3 months after the isolation of the
linezolid-resistant MRSA (LR-MRSA) isolate. In order to compare the perfor-
mance characteristics of commonly used susceptibility tests, determination of the
linezolid MIC for the cfr-carrying LR-MRSA isolate (isolate CM-05) was per-
formed both by broth and agar dilution methods (5) and by Etest. Isolates of S.
aureus recovered from surveillance studies carried out in Colombian hospitals
between 2001 and 2004 (1, 6) were investigated for their resistance to chloram-
phenicol and linezolid (a phenotypic characteristic of staphylococci harboring
the cfr gene). The double-diffusion test (D-test) was performed by following the
recommendations of Montanari et al. (18), with minor modifications. Erythro-
mycin and clindamycin disks (15 and 2 g, respectively; BBL Microbiology
Systems, Cockeysville, MD) were placed 15 mm apart on a Mueller-Hinton agar
(Biomedics, SL) plate. A modified D-test with erythromycin and linezolid disks
(15 and 30 g, respectively) was performed with isolate CM-05.
Molecular typing and PCR amplification of the cfr and erm genes. The total
DNA of each isolate was extracted and was digested with SmaI by following
previously described protocols (6). After digestion, the total DNAs were sepa-
rated by agarose electrophoresis on a CHEF-DR II system (Bio-Rad Laborato-
ries, Hercules, CA) with the following conditions: for block 1, a run time of 10 h,
a switch time of 5 to 15 s, and a voltage of 6 V/cm; for block 2, a run time of 13 h,
a switch time of 15 to 60 s, and a voltage of 6 V/cm. The gels were stained and
photographed by using the standard methodology. Cluster analysis of the mac-
rorestriction profiles was performed, and the profiles were analyzed by using the
Dice similarity coefficient with pulsed-field gel electrophoresis (PFGE) band
similarity software (Fingerprinting II software; Bio-Rad Laboratories) by using a
cutoff of 75% as the criterion for cluster formation. Final PFGE interpretation
was based on the criteria of Tenover et al. (27). S. aureus NCTC 8325-4 was used
as a control strain to assess the fragment sizes. Representative MRSA isolates of
the most common PFGE clones circulating in South America (HPV120, Iberian
clone; HSJ93, Brazilian clone; HDE 3, pediatric clone; and CHL93, Chilean
clone) were included for comparison.
Multilocus sequence typing was performed for isolate MRSA CM-05 by fol-
lowing the methodology described previously (7). Briefly, PCR amplifications of
seven housekeeping genes (arcC, aroE, glpF, gmk, pta, tpi, yqiL) were performed,
and the amplicons were then sequenced by an automated method. The sequence
type (ST) was determined by use of the combination of the seven alleles (7), and
each unique allelic profile was designated an ST. SCCmec types I to IV were
evaluated by a previously reported multiplex PCR assay (19) to determine their
staphylococcal chromosomal cassette mec type (types I to IV).
Total genomic DNA from strain CM-05 was used as the template for the
amplification of the cfr gene with the oligonucleotide primers described previ-
ously (13) and by using the following conditions: 5 min at 94°C; 35 cycles of 30 s
at 94°C, 30 s at 55°C, and 1 min at 72°C; and a final extension at 72°C for 5 min.
The presence of erythromycin resistance genes was also determined by PCR.
Primer sequences targeting erm(A), erm(B), and erm(C) (which encode methyl-
ases) and msrA (which encodes an efflux pump) were used according to the
recommendations of Martineau et al. (16). Fifteen isolates of MRSA, 1 MSSA
isolate recovered in the same unit immediately after MRSA CM-05 was identi-
fied, and 68 clinical isolates of chloramphenicol-resistant MRSA collected in
Colombian hospitals from 2001 to 2004 (1, 6) were investigated for the presence
of the cfr gene by PCR.
RESULTS AND DISCUSSION
Linezolid resistance in the absence of oxazolidinone expo-
sure and surveillance. As described previously, MRSA CM-05
did not exhibit any mutations in domain V of the 23S rRNA
(28). The identification of the cfr gene, which encodes an
rRNA methylase, in this isolate recovered from a patient after
such a short exposure to linezolid (28) indicates that the gene
was also most likely acquired by the isolate under a selective
pressure that did not involve exposure to oxazolidinones. An
alternative explanation is that the strain was selected in an
unidentified patient exposed to linezolid and was then passed
on to the case patient. However, we did not find any evidence
of the presence of cfr in any of the clinical isolates of MRSA
previously recovered in Colombia or isolated around the time
that the first isolate was discovered (see below), making this
alternative possibility less likely. Although linezolid resistance
in the absence of oxazolidinone exposure had been docu-
mented in Enterococcus spp. (2, 10, 21), it has not previously
been described in MRSA. In the case of enterococci, linezolid
resistance emerged in hospitalized patients but was also de-
scribed in a patient with no risk factors associated with the
selection of resistant organisms (hospitalization, receipt of
multiple antibiotics, or comorbidities) (2). As opposed to
MRSA CM-05, all linezolid-resistant enterococci described in
the absence of oxazolidinone exposure carried the G2576U
mutation, suggesting that this rRNA mutation may be selected
by factors other than exposure to linezolid.
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In Europe, cfr was initially found on a plasmid of a bovine
isolate of Staphylococcus sciuri (14, 24), and its acquisition by
animal isolates appears to have been influenced by the use of
florfenicol in the veterinary industry (23) and the mobility of
the DNA encoding it (12). Chloramphenicol is still used in
Colombia, especially in the pediatric population, and although
the use of phenicols in the veterinary industry is unknown in
Colombia, it is likely that the acquisition of cfr might have been
influenced by the use of the phenicol group of antibiotics in
animals and humans. The pleuromutilins and streptogramins
(which could also select for the presence of cfr) are not used in
humans in Colombia, and their use in the veterinary industry is
also unknown.
Since cfr was initially characterized from animal isolates, we
sought to determine possible animal contacts by the patient.
The patient had no pets at home, and the family reported no
visits of animals from surrounding neighbors. The patient lived
with her son, a male adult (age, 37 years); his female partner
(age, 24 years); and a nephew (age, 6 years). Nasal and inguinal
samples revealed the presence of colonization by chloram-
FIG. 1. PFGE of MRSA isolates recovered after identification of the LR-MRSA isolate (isolate CM-05; arrow). The isolate nomenclature is
the same as that in Table 1. Additional isolates include isolate P, MRSA CHL93, representative of the Chilean clone; isolate S, MRSA HDE3,
representative of the pediatric clone; and isolate T, S. aureus NCTC 8325, used as a control.
TABLE 1. Susceptibilities of clinical isolates of Staphylococcus aureus
Isolate Source
MIC (g/ml)/interpretationa
OXA VAN TEI LNZ CIP ERY CLI GEN RIF CHL TET SXT
A Surgical wound 8/R 0.5/S 0.5/S 2/S 0.5/S 0.5/S 0.12/S 64/R 0.015/S 8/S 32/R 0.5/9.5/S
B Soft tissue 0.5/S 0.5/S 1/S 2/S 0.5/S 0.25/S 0.06/S 0.5/S 0.015/S 16/I 0.25/S 0.5/9.5/S
C Surgical wound 64/R 1/S 0.5/S 2/S 16/R 64/R 32/R 64/R 0.015/S 16/I 0.12/S 0.5/9.5/S
D Blood 64/R 1/S 0.5/S 2/S 32/R 64/R 32/R 64/R 0.015/S 16/I 0.12/S 0.5/9.5/S
E Bone 64/R 0.5/S 1/S 2/S 32/R 64/R 32/R 64/R 0.015/S 16/I 0.12/S 0.5/9.5/S
F Skin abscess 64/R 0.5/S 1/S 2/S 32/R 64/R 32/R 64/R 0.015/S 16/I 0.12/S 0.5/9.5/S
G Intraocular fluid 64/R 0.5/S 1/S 2/S 16/R 64/R 32/R 64/R 0.015/S 16/I 0.12/S 0.5/9.5/S
H Blood 64/R 0.5/S 1/S 2/S 16/R 64/R 32/R 64/R 0.015/S 16/I 0.12/S 0.5/9.5/S
I Blood 64/R 0.5/S 1/S 2/S 32/R 32/R 32/R 64/R 0.015/S 16/I 0.12/S 0.5/9.5/S
J Soft tissue 64/R 1/S 1/S 2/S 32/R 64/R 32/R 64/R 0.015/S 8/S 32/R 0.5/9.5/S
K Surgical wound 64/R 2/S 0.5/S 2/S 32/R 64/R 32/R 64/R 0.015/S 16/I 64/R 0.5/9.5/S
Lb Tracheal aspirate 64/R 1/S 0.5/S 16/R 32/R 64/R 32/R 64/R 0.0075/S 64/R 0.12/S 0.5/9.5/S
M Urine 64/R 2/S 1/S 2/S 32/R 64/R 32/R 1/S 0.015/S 16/I 0.25/S 0.5/9.5/S
N Blood 64/R 1/S 1/S 2/S 32/R 64/R 32/R 64/R 4/R 16/I 64/R 0.5/9.5/S
O Soft tissue 64/R 0.5/S 1/S 2/S 16/R 64/R 32/R 64/R 0.015/S 16/I 64/R 0.5/9.5/S
Q Bone 64/R 1/S 1/S 2/S 32/R 64/R 32/R 64/R 0.015/S 16/I 0.12/S 1/19/S
R Peritoneal fluid 64/R 0.5/S 0.5/S 2/S 16/R 64/R 32/R 64/R 0.12/S 8/S 0.12/S 0.5/9.5/S
a Abbreviations: OXA, oxacillin; VAN, vancomycin; TEI, teicoplanin; LNZ, linezolid; CIP, ciprofloxacin; ERY, erythromycin; CLI, clindamycin; GEN, gentamicin;
RIF, rifampin; CHL, chloramphenicol; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; R, resistant; S, susceptible; I, intermediate.
b Isolate L is LR-MRSA isolate CM-05, and the MIC of linezolid is underlined.
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phenicol-susceptible MSSA in the three individuals. Suscepti-
bility to chloramphenicol indicated that these isolates did not
carry cfr, since this gene confers resistance to both chloram-
phenicol and florfenicol (12). In support of this conclusion, we
were unable to detect the cfr gene by PCR in any of these
isolates. Similarly, we screened a total of 16 S. aureus clinical
isolates recovered from patients in the same unit where the
index patient was hospitalized for the presence of the cfr gene
by PCR. The isolates were recovered after the identification of
MRSA CM-05 (Table 1). These nosocomial isolates were sus-
ceptible to linezolid, did not exhibit high-level resistance to
chloramphenicol (Table 1), and also lacked the cfr gene.
In order to determine if cfr was prevalent in earlier MRSA
isolates from Colombia, we performed a PCR assay targeting
the cfr gene using 68 chloramphenicol-resistant MRSA isolates
recovered in Colombian hospitals between 2001 and 2004 (1,
6). Again, we were unable to detect the presence of cfr in these
clinical isolates, indicating that the gene is rare in clinical
isolates of Colombian MRSA and that the acquisition of this
gene might have occurred recently. This finding is in agree-
ment with the findings of studies performed in Germany,
where cfr was first identified, which reported that the gene was
not found in any of 114 human isolates of S. aureus studied but
was present in 11 of 188 staphylococci from animal sources
(12).
Phenotypic and genotypic characteristics of LR-MRSA CM-
05. As was shown previously (28), linezolid-resistant clinical
isolate CM-05 was found to be resistant to ciprofloxacin, eryth-
romycin, clindamycin, gentamicin, chloramphenicol, and lin-
ezolid (Table 1). MRSA CM-05 exhibited the constitutive mac-
rolide-lincosamide-streptogramin B (cMLSB) phenotype, and
we were able to detect both the erm(A) and the erm(B) genes.
This was an unusual finding, since previous studies have shown
that macrolide resistance in Colombian nosocomial isolates of
MRSA was mediated by the presence of the erm(A) gene, the
erm(C) gene, or a combination of the erm(A) and msr(A)
genes but not the erm(B) gene (all isolates exhibited the
cMLSB phenotype) (22). Conversely, macrolide resistance me-
diated by the erm(B) gene was found in all erythromycin-
resistant enterococci (22). This finding is consistent with our
previous hypothesis that cfr might have originated from an
enterococcal isolate (28). The horizontal transfer of the vanA
operon from Enterococcus faecalis to MRSA has been de-
scribed previously (4), and this could represent another exam-
ple of the horizontal exchange of antibiotic resistance genes
between enterococcal and staphylococcal species.
PFGE of isolate MRSA CM-05 and 16 other S. aureus iso-
lates from the same unit where the patient was hospitalized
revealed that CM-05 and 88% of the other S. aureus isolates
had an electrophoretic pattern identical to that of the isolates
belonging to the Chilean clone (Fig. 1), but only CM-05 was
resistant to linezolid. Multilocus sequence typing of isolate
CM-05 indicated that it belonged to ST5 (allelic profile 1-4-
14-4-12-2-10) and carried staphylococcal chromosomal cas-
sette mec type I (ST5-MRSA-I). This ST5-MRSA-I clone ini-
tially emerged in the southern cone of South America (26) and
appears to have subsequently spread to the northern areas of
the continent (6). The molecular typing information confirmed
that the acquisition of cfr is likely to be a recent event in
Colombia.
Detection of linezolid resistance. The MRSA CM-05 isolate
had a linezolid MIC of 16 g/ml and was initially detected by
an automated method (Vitek system; BioMe´rieux, Marcy
l’Etoile, France). Subsequently, both the broth and the agar
dilution methods yielded similar results. When the organism
was tested by Etest, it was reported to be susceptible, with an
MIC of 2 g/ml after 24 h of incubation. A second halo of
inhibition was observed after 48 h of incubation, with an MIC
of 16 g/ml (Fig. 2). A modified D-test with a disk of linezolid
(30 g) next to a disk of erythromycin (15 g) showed no
evidence of induction (the D-test was negative), and the result
of the disk diffusion test was interpreted as susceptible at 24 h
of incubation. The results indicate that disk diffusion suscep-
tibility tests or Etest might not detect cfr-mediated linezolid
resistance when standard procedures are used and that a
longer time of incubation may be needed. The appearance of
a double zone of inhibition by Etest may indicate that expres-
sion of the mlr operon is under controlled regulation and
requires the presence of unknown additional factors. The pres-
FIG. 2. Etest of LR-MRSA CM-05. The first halo of inhibition was
evident at 24 h (interpreted as an MIC of 2 g/ml; black arrow). After
an additional 24 h of incubation, a second halo of growth was identified
(MIC, 16 g/ml; arrowhead).
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ence of a “heterogeneous” subpopulation of linezolid-resistant
cells within MRSA CM-05 could also be possible, since the
differential expression of resistance genes is a common feature
of MRSA (9).
In summary, we describe the clinical and microbiological
aspects of the first human clinical isolate of MRSA exhibiting
resistance to linezolid mediated by the cfr gene, which encodes
a 23S rRNA methyltransferase; resistance emerged in a coun-
try where linezolid usage is very limited. Detection of the
resistance phenotype might be compromised by the use of
regular disk diffusion tests or Etest. The surveillance studies
indicate that this mechanism of resistance is still extremely rare
in MRSA but that clinicians should be aware of the potential
for the dissemination from animals to humans due to the
ability for horizontal gene transfer to occur between staphylo-
coccal and enterococcal isolates of both animal and human
origin.
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